Cancer researchers have carried out the first comprehensive study of the changes seen in the DNA of a patient with mast cell leukemia, an extremely aggressive subtype of acute myeloid leukemia with a very poor prognosis. Their genomic survey has helped identify two previously unknown mutations that could directly influence patient response to currently available therapeutic drugs.